Boyds opens US office
Boyds has announced the opening of its US office, based in the Philadelphia area, and welcomes Katy Rudnick who is appointed Vice President and Head of US Regulatory Affairs to head up the newly established US company. Since Boyds was established in 2005, the company has worked with US companies seeking to develop and gain […]
Boyds Ireland relocates to Talent Garden Dublin
Boyds has moved into Dublin’s Talent Garden, a workplace community for innovators and entrepreneurs. UK-headquartered Boyds established its Irish office in 2019 with the aim of ensuring continuity of service to its clients once the UK had left the EU. During that time, Boyds Ireland has seen significant growth, with predicted further growth for the […]
Susan Tansey elected as Fellow of the Royal College of Paediatrics and Child Health
We are delighted to share the news that Susan Tansey is being elected as a Fellow of the Royal College of Paediatrics and Child Health from the 1st July. Susan, who joined Boyds as a Consultant Pharmaceutical Physician in 2019, is a paediatrician with specific expertise in respiratory paediatrics and neonatology. Since leaving her post […]
Experienced regulatory professionals join the Boyds team
Boyds is delighted to announce the appointments of Shalini Gupta and Sarah Stevenson to our regulatory team in response to recent growth and the continued increase in demand for our dedicated regulatory services. Shalini Gupta joins the company as Senior Manager, Regulatory Affairs, and brings over 10 years of industry experience in regulatory submissions across […]
Professor Alan Boyd awarded the Fellowship of the Academy of Medical Sciences
Boyds’ Founder and President, Professor Alan Boyd, has been awarded the Fellowship of the Academy of Medical Sciences. This prestigious award recognises Professor Boyd’s contributions to medical science and medicines and has been awarded to him based on his significant involvement in supporting the development of medicines across several therapeutic areas and most notably in […]
Boyds supports COVID-19 human infection study
Boyds is working in collaboration with Wellcome on a COVID-19 human infection study which aims to investigate the immunity provided by previous COVID-19 infections to increase our knowledge and understanding of the disease and how we can treat and prevent it. Human infection studies are also known as human challenge trials and involve the deliberate […]
Opportunities in Clinical Research
One Nucleus recently hosted their Building Life Science Adventures Conference which focused on industry career opportunities, such as clinical research. The two-day event was held online and brought together panels of students, early career speakers, employers and universities to engage in lively discussions. Alan Boyd was invited to chair a session focused on opportunities in clinical […]
Boyds appoints Neil Chakrabarti as Chief Financial Officer
Boyds is delighted to announce the appointment of Neil Chakrabarti as Chief Financial Officer. The appointment comes as the company reports a record-breaking 25 percent growth in turnover as demand for its specialist services continues to grow. Neil is an experienced financial leader and has worked with a number of businesses across the sector including […]
Supporting the development and regulatory activities for the AstraZeneca-Oxford COVID-19 vaccine
The approval in December for the emergency use of the AstraZeneca-Oxford COVID-19 vaccine by the MHRA provided another key milestone in the response to the pandemic. With the COVID-19 vaccine now in wide use across the UK, Professor Alan Boyd reflects on the team’s involvement in this vital and ground-breaking project. Professor Alan Boyd said, […]
Alan Boyd joins Taysha Gene Therapies’ independent scientific advisory board
Professor Alan Boyd has joined Taysha Gene Therapies’ newly formed independent scientific advisory board. Taysha Gene Therapies, Inc., a patient-centric gene therapy company focused on developing and commercialising AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations, has announced the formation of an independent Scientific […]
